BCRX
Price
$8.94
Change
-$0.08 (-0.89%)
Updated
Jul 3 closing price
Capitalization
1.87B
27 days until earnings call
CRNX
Price
$29.80
Change
+$0.36 (+1.22%)
Updated
Jul 3 closing price
Capitalization
2.76B
35 days until earnings call
Interact to see
Advertisement

BCRX vs CRNX

Header iconBCRX vs CRNX Comparison
Open Charts BCRX vs CRNXBanner chart's image
BioCryst Pharmaceuticals
Price$8.94
Change-$0.08 (-0.89%)
Volume$1.41M
Capitalization1.87B
Crinetics Pharmaceuticals
Price$29.80
Change+$0.36 (+1.22%)
Volume$461.1K
Capitalization2.76B
BCRX vs CRNX Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. CRNX commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Buy and CRNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (BCRX: $8.94 vs. CRNX: $29.80)
Brand notoriety: BCRX: Notable vs. CRNX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 28% vs. CRNX: 63%
Market capitalization -- BCRX: $1.87B vs. CRNX: $2.76B
BCRX [@Biotechnology] is valued at $1.87B. CRNX’s [@Biotechnology] market capitalization is $2.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CRNX’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 5 bearish.
  • CRNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than CRNX.

Price Growth

BCRX (@Biotechnology) experienced а -7.45% price change this week, while CRNX (@Biotechnology) price change was -2.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

CRNX is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.76B) has a higher market cap than BCRX($1.87B). BCRX YTD gains are higher at: 18.883 vs. CRNX (-41.717). BCRX has higher annual earnings (EBITDA): 47.6M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. BCRX (295M). CRNX has less debt than BCRX: CRNX (50.8M) vs BCRX (795M). BCRX has higher revenues than CRNX: BCRX (503M) vs CRNX (760K).
BCRXCRNXBCRX / CRNX
Capitalization1.87B2.76B68%
EBITDA47.6M-373.49M-13%
Gain YTD18.883-41.717-45%
P/E RatioN/AN/A-
Revenue503M760K66,184%
Total Cash295M1.27B23%
Total Debt795M50.8M1,565%
FUNDAMENTALS RATINGS
BCRX vs CRNX: Fundamental Ratings
BCRX
CRNX
OUTLOOK RATING
1..100
5354
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
7468
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
5165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for CRNX (91) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as BCRX (74) in the Biotechnology industry. This means that CRNX’s stock grew similarly to BCRX’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as BCRX (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (51) in the Biotechnology industry is in the same range as CRNX (65) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew similarly to CRNX’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that BCRX’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCRNX
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFSVX48.600.25
+0.52%
DFA US Small Cap Value I
PNBCX28.99N/A
N/A
Virtus NFJ Large-Cap Value C
TRGPX22.30N/A
N/A
Nuveen Quant Mid Cap Growth Premier
PRDAX11.92N/A
N/A
Principal Diversified Real Asset A
PEDGX13.21N/A
N/A
Principal Edge MidCap Institutional